Bioactive Suture with Added Innate Defense Functionality for the Reduction of Bacterial Infection and Inflammation
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 6,51 MB, PDF-dokument
Surgical site infections (SSI) are a clinical and economic burden. Suture-associated SSI may develop when bacteria colonize the suture surface and form biofilms that are resistant to antibiotics. Thrombin-derived C-terminal peptide (TCP)-25 is a host defense peptide with a unique dual mode of action that can target both bacteria and the excessive inflammation induced by bacterial products. The peptide demonstrates therapeutic potential in preclinical in vivo wound infection models. In this study, the authors set out to explore whether TCP-25 can provide a new bioactive innate immune feature to hydrophilic polyglactin sutures (Vicryl). Using a combination of biochemical, biophysical, antibacterial, biofilm, and anti-inflammatory assays in vitro, in silico molecular modeling studies, along with experimental infection and inflammation models in mice, a proof-of-concept that TCP-25 can provide Vicryl sutures with a previously undisclosed host defense capacity, that enables targeting of bacteria, biofilms, and the accompanying inflammatory response, is shown.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 2300987 |
Tidsskrift | Advanced Healthcare Materials |
Vol/bind | 12 |
Udgave nummer | 31 |
Antal sider | 20 |
ISSN | 2192-2640 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
J.P. and G.P. contributed equally to this work. This work was supported by grants from the Swedish Research Council (project 2017–02341, 2020‐02016), the Edvard Welanders Stiftelse and Finsenstiftelsen (Hudfonden), the Royal Physiographic Society, the Crafoord and Österlund Foundation, and the Swedish Government Funds for Clinical Research (ALF). Support from the Swedish National Infrastructure for Biological Mass Spectrometry (BioMS) and BII (A*STAR) core funds is gratefully acknowledged. In silico simulations were performed on the supercomputer Fugaku provided by RIKEN through the HPCI System Research Project (Project ID: hp220297). The authors acknowledge BioRender's assistance in creating the ToC figure.
Publisher Copyright:
© 2023 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH.
ID: 370470826